[1] |
王凤霞,姜淑霞.便秘的预防及饮食调护[J]. 中国医药导报, 2008, 5(13):151-152.
|
[2] |
王品,张有成. 慢传输型便秘的病因及发病机制研究进展, 2012, 12(30): 5994-5996;5984.
|
[3] |
万锦洲,马锦星,刘卉.一种简易的小鼠便秘模型[J]. 中国药理学通报, 1994, 10(1):71-72.
|
[4] |
张卫平,江滨.五羟色胺与慢性便秘[J]. 世界华人消化杂志, 2011, 19(24): 2551-2554.
|
[5] |
雷怀成,易建华,刘涛.运动迟缓型便秘结肠壁内5-羟色胺和P物质的免疫组织化学研究[J]. 中华组织化学与细胞化学杂志, 2000, 9(4):405-407.
|
[6] |
童卫东,张胜本,张连阳, 等.慢传输型便秘结肠肌间丛NOS、SOM、5-HT免疫反应性变化[J]. 中华胃肠外科杂志, 1999, 2(3):168-170.
|
[7] |
Crowell MD,Shetzline MA,Moses PL, et al. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function[J]. Current Opinion in Investigational Drugs, 2004, 5(1): 55-60.
|
[8] |
陆敏,王德明,王焱, 等.便秘型肠易激综合征与5-HT的相关性研究[J]. 山东医药, 2009, 49(32):32-33.
|
[9] |
Sjölund K,Fasth S,Ekman R, et al.Neuropeptides in idiopathic chronic constipation (slow transit constipation)[J]. Neurogastroenterology & Motility, 1997, 9(3):143-150.
|
[10] |
Shin A.,Camilleri M.,Kolar G., et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation[J]. Alimentary Pharmacology and Therapeutics, 2014, 39(3):239-253.
|
[11] |
Shin A,Acosta A,Camilleri M, et al.A Randomized Trial of 5-Hydroxytryptamine 4–Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation[J]. Clinical Gastroenterology and Hepatology, 2015, 13(4):701-708.
|
[12] |
Lee MJ,Cho KH,Park HM, et al.Pharmacological profile of DA-6886, a novel 5-HT 4 receptor agonist to accelerate colonic motor activity in mice[J]. European Journal of Pharmacology, 2014, 735:115-122.
|
[13] |
Hoffman JM,Tyler K,MacEachern SJ, et al. Activation of colonic mucosal 5-HT 4 receptors accelerates propulsive motility and inhibits visceral hypersensitivity[J]. Gastroenterology, 2012, 142(4): 844-854.
|